Key result
Benralizumab prompts LVEF recovery to ~50% in severe EGPA-associated cardiomyopathy.
Why the study?
Targeted eosinophil depletion with benralizumab may reverse advanced EGPA-associated cardiomyopathy, but evidence is limited to case reports.
Does benralizumab improve ventricular function in patients with EGPA-associated cardiomyopathy?
Case Report (n=1)
Does benralizumab improve ventricular function in patients with EGPA-associated cardiomyopathy?
Targeted eosinophil depletion with benralizumab can induce complete functional and structural recovery in patients with advanced EGPA-associated cardiomyopathy, allowing for independence from steroid therapy.
Answers are grounded in this paper and cite their sources.
Supports targeted eosinophil depletion in EGPA cardiomyopathy; leaves open prospective trials before clinical adoption.
Background: We report a case to demonstrate that targeted eosinophil depletion with Benralizumab (anti-IL-5 receptor α therapy) can induce the complete functional and structural reversal of advanced EGPA-associated cardiomyopathy. Case Presentation: A 56-year-old woman with a decade-long history of EGPA presented with progressive nonischemic dilated cardiomyopathy and a nadir ejection fraction of 25–30%. Cardiac MRI demonstrated diffuse nonischemic late gadolinium enhancement consistent with eosinophil-mediated myocardial injury. Despite the optimization of guideline-directed medical therapy, complete recovery was not achieved until benralizumab was initiated. Following biologic therapy, the ejection fraction recovered to 50% and severe mitral regurgitation regressed to mild. The exercise capacity was preserved throughout, with a peak VO2 of 117% and 111% of predicted before and after biologic therapy, respectively. The patient remains in NYHA Class I at the one-year follow-up. Discussion: We describe a case with EGPA-associated non-ischemic cardiomyopathy treated with benralizumab achieving the complete recovery of ventricular function and achieving the complete independence of steroid therapy. Conclusions: This case emphasizes the importance of identifying the inflammatory etiology of cardiomyopathy, optimizing GDMT systematically, and considering targeted biologic therapy directed at the underlying disease.
No takes yet. Share an insight, caveat, or question.
Bangari et al. (2026) conducted a case report in EGPA-associated cardiomyopathy (n=1). Benralizumab was evaluated on Ejection fraction and functional recovery. Benralizumab therapy for EGPA-associated cardiomyopathy induced structural and functional reversal, with ejection fraction recovering from 25-30% to 50% at 1-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: